News
MIMOSA™ by TaraCares exits beta, as start-up gears up for expansion
The platform will allow women to integrate their health data with intelligence from academic research and clinical excellence
MIMOSA™, a first-of-its-kind virtual precision health platform developed by TaraCares Global, has exited its beta phase, as the start-up prepares for launch in 11 international markets.
MIMOSA™ aims to reimagine how female individuals of all ages, ethnicities and genders enter their unique menopause journey.
Empowered with menopause health literacy individualised to the user’s flavour of the menopause transition and accompanying life circumstances, the platform will provide women with a longitudinal Menopause Health Graph™ and Menopause Health Risk Profile™ that integrates their health data with intelligence from academic research and clinical excellence.
A B2B HealthTech SaaS platform, MIMOSA™ is currently available through employers. It has received glowing feedback from clinicians and individual users during the private launch that witnessed a user engagement rate of 84.38 per cent in 11 countries, including the four UK nations.

MIMOSA™ by TaraCares aims to educate and empower women throughout all the stages of the menopause
Dr/Prof. Vikram Sinai Talaulikar, a reproductive specialist at UCLH who has worked closely with TaraCares as a clinical advisor during the design and development of MIMOSA™ said: “The platform is easy to use, lovely images and colours, simple non-technical language so anyone can use it.

Dr Vikram Talaulikar, MD, FRCOG, PhD
“Out of comparable apps I have seen, MIMOSA™ stands out as comprehensive, inclusive, and easy-to-use,” Vikram, a certified menopause specialist by the British Menopause Society (BMS) and honorary associate professor at UCL, also added.
A user involved in the Innovate UK funded research study led by TaraCares said: “The ‘trace your health’ feature is so easy to use. It has certainly helped me understand the symptoms I could be experiencing while staying focussed on my self-care and nutritional needs. Journaling my thoughts felt so reassuring and calming.”
Business impact
TaraCares is currently in discussions with several public and private organisations including FTSE100 companies in the UK for trial pilots of MIMOSA™.
Last week, its founder and CEO, Jyoti Sharma, who has Indian origins and still reads Sanskrit, the ancient classical language of India in her spare time, announced the value-set that guides the decisions at TaraCares, adding “Be KRiiYa = Be Kind, Be Resilient, Be Intentional, Be Inspirational, Be You, Be Accountable.”
The company has been successful in signing established menopause corporate advisors and consultants as strategic alliances for their initial market penetration strategy, including Kirsty Dixon and Sally Duffin who have been appointed as strategic collaborators and members of the care team.
Describing herself as a postmenopausal woman with 12 years perimenopause experience under her belt, Dixon says her personal journey is her driving force to raise awareness and educate individuals and employers to ensure people receive research-based information and have access to the support they need to thrive.

Kirsty Dixon, strategic collaborator and member of the care team at TaraCares Global
Following on from her work at the University of York, where she changed the culture around menopause through awareness raising and setting up support initiatives, she set up Pause for Thought Consultancy in 2022, to help employers to do the same.
“I love everything about TaraCares. MIMOSA™ is easy to use and everything is research focused so any information is up-to-date and above all correct,” Dixon said.
“I class myself as a menopause educator so look forward to working with TaraCares. Also to be a critical friend and work alongside them to provide the best service for all who need menopause education and support.”
Duffin, another strategic collaborator, is a qualified registered nutritionist/nutritional therapist. She founded Nutrition in York to support support clients with digestive wellbeing, mental health, stress management, and hormonal issues.

Sally Duffin, strategic collaborator and member of the care team at TaraCares Global
After a short break from clinical work to write her book Natural Nutrition for Perimenopause – What to Eat to Feel Good and Stay Sane, she returned to private nutrition practice to focus on menopause support.
Duffin is a firm believer in the power of small steps that build healthy habits, understands the challenges clients face when trying to eat well and this is what excites her to be part of the team at TaraCares.
“TaraCares is built on a strong ethical foundation and has such a clear vision of what menopause care can and should look like. It’s exciting to be part of the team,” she said.
“We aim to support the whole menopause experience and provide accessible knowledge that users need to make informed, holistic decisions about their menopause transition.”
With MIMOSA™ expected to launch this summer, Sharma has revealed that several companies her team has been speaking to are already using solutions from competitors in the menopause space that have failed to deliver on the evidence base and benefits of the business case, highlighting the need for change and innovation.
The MIMOSA™ platform will be available for both Android and iOS. To find out more, email Jyoti Sharma at jsharma@taracares.co.uk.

Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






